Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Mol Cancer ; 21(1): 153, 2022 07 25.
Artículo en Inglés | MEDLINE | ID: mdl-35879762

RESUMEN

BACKGROUND: Cell division cycle 6 (CDC6) has been proven to be associated with the initiation and progression of human multiple tumors. However, it's role in glioma, which is ranked as one of the common primary malignant tumor in the central nervous system and is associated with high morbidity and mortality, is unclear. METHODS: In this study, we explored CDC6 gene expression level in pan-cancer. Furthermore, we focused on the relationships between CDC6 expression, its prognostic value, potential biological functions, and immune infiltrates in glioma patients. We also performed vitro experiments to assess the effect of CDC6 expression on proliferative, apoptotic, migrant and invasive abilities of glioma cells. RESULTS: As a result, CDC6 expression was upregulated in multiple types of cancer, including glioma. Moreover, high expression of CDC6 was significantly associated with age, IDH status, 1p/19q codeletion status, WHO grade and histological type in glioma (all p < 0.05). Meanwhile, high CDC6 expression was associated with poor overall survival (OS) in glioma patients, especially in different clinical subgroups. Furthermore, a univariate Cox analysis showed that high CDC6 expression was correlated with poor OS in glioma patients. Functional enrichment analysis indicated that CDC6 was mainly involved in pathways related to DNA transcription and cytokine activity, and Gene Set Enrichment Analysis (GSEA) revealed that MAPK pathway, P53 pathway and NF-κB pathway in cancer were differentially enriched in glioma patients with high CDC6 expression. Single-sample gene set enrichment analysis (ssGSEA) showed CDC6 expression in glioma was positively correlated with Th2 cells, Macrophages and Eosinophils, and negative correlations with plasmacytoid dendritic cells, CD8 T cells and NK CD56bright cells, suggesting its role in regulating tumor immunity. Finally, CCK8 assay, flow cytometry and transwell assays showed that silencing CDC6 could significantly inhibit proliferation, migration, invasion, and promoted apoptosis of U87 cells and U251 cells (p < 0.05). CONCLUSION: In conclusion, high CDC6 expression may serve as a promising biomarker for prognosis and correlated with immune infiltrates, presenting to be a potential immune therapy target in glioma.


Asunto(s)
Neoplasias Encefálicas , Glioma , Biomarcadores , Neoplasias Encefálicas/metabolismo , Proteínas de Ciclo Celular/genética , Glioma/patología , Humanos , FN-kappa B , Proteínas Nucleares/genética , Pronóstico
2.
Medicine (Baltimore) ; 99(14): e19413, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-32243360

RESUMEN

The aim of this observational study was to test whether ABO blood type was a prognostic factor for pancreatic ductal adenocarcinoma (PDAC) patients and whether other risk factors could influence pancreatic cancer patients' survival. This study included 610 patients who were diagnosed as pancreatic cancer and had undergone radical surgery. Patients' characteristics included age, gender, tumor stage, tumor grade, adenosquamous carcinoma (ASC) status, preoperative serum carbohydrate antigen 19-9 (CA19-9) levels, preoperative serum carcinoembryonic antigen (CEA) levels, ABO blood type, smoking status, and drinking status were analyzed in this study. Cox proportional hazards regression model and Kaplan-Meier method were used to evaluate the role of prognostic factors. For pancreatic cancer patients undergoing radical surgery, the overall survival was worse for ASC patients than PDAC patients (Log-rank = 11.315, P < .001). Compared with ASC patients (Log-rank < 0.001, P = .996), PDAC patients can benefit from chemotherapy (Log-rank = 17.665, P < .001). For PDAC patients, O blood type had better overall survival than non-O blood type (Log-rank = 4.153, P = .042). Moreover, the group with higher serum levels of CA19-9 had poor prognosis compared to another group with low serum CA19-9 (Log-rank = 4.122, P = .042). Higher CEA levels indicated poor prognosis (Log-rank = 13.618, P < .001). In conclusion, ASC status was associated with overall survival of pancreatic cancer patients and cannot benefit from postoperative chemotherapy. Non-O blood type was a prognostic factor for PDAC patients.


Asunto(s)
Carcinoma Ductal Pancreático/mortalidad , Carcinoma Ductal Pancreático/patología , Neoplasias Pancreáticas/mortalidad , Neoplasias Pancreáticas/patología , Sistema del Grupo Sanguíneo ABO/sangre , Adulto , Factores de Edad , Anciano , Consumo de Bebidas Alcohólicas/epidemiología , Antígeno CA-19-9/sangre , Antígeno Carcinoembrionario/sangre , Carcinoma Adenoescamoso/patología , Carcinoma Ductal Pancreático/epidemiología , Carcinoma Ductal Pancreático/cirugía , Fumar Cigarrillos/epidemiología , Femenino , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Clasificación del Tumor , Estadificación de Neoplasias , Neoplasias Pancreáticas/epidemiología , Neoplasias Pancreáticas/cirugía , Modelos de Riesgos Proporcionales , Factores de Riesgo , Factores Sexuales
3.
J BUON ; 24(2): 424-430, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31127986

RESUMEN

Gliomas are tumors with high incidence and poor prognosis among primary brain tumors and they present difficulties in surgical removal, having also high recurrence rate. The efficacy of various treatments on high-grade gliomas is not satisfactory. Some studies have found that age, surgery, radiotherapy, chemotherapy and other factors, such as tumor molecular pathology, have a certain impact on the recurrence of high-grade gliomas, and a common concern in the studies of high-grade gliomas is that one single treatment often has low efficacy. However, with the development of molecular biology, there is a deeper understanding of the pathogenesis of these tumors, and molecular targeted therapy has attracked impressive attention. The treatment of recurrent high-grade gliomas is also more abundant , Diversity of treatment options than before. Oncolytic virus therapy, stem cell therapy, immunotherapy and electric field therapy are now available. These emerging treatments are expected to improve the prospect of treating recurrent high-grade gliomas.


Asunto(s)
Glioma/terapia , Terapia Molecular Dirigida , Recurrencia Local de Neoplasia/terapia , Tratamiento Basado en Trasplante de Células y Tejidos/métodos , Terapia Combinada , Glioma/genética , Glioma/patología , Humanos , Inmunoterapia/métodos , Recurrencia Local de Neoplasia/patología , Viroterapia Oncolítica/métodos
4.
Guang Pu Xue Yu Guang Pu Fen Xi ; 30(11): 2950-3, 2010 Nov.
Artículo en Chino | MEDLINE | ID: mdl-21284160

RESUMEN

Cooking loss and tenderness are important quality characteristics of fresh pork. To find a rapid, non-destructive and non-contaminated method to measure them, visible/near infrared spectroscopy was proposed for measurement of cooking loss and tenderness of vacuum-packed pork loin. The acquired raw spectra were pretreated by Savisky-Golay smoothing, second derivative and MSC, respectively using the software of Unscrambler 9.6. A total of 104 samples were used in the experiment. The samples were divided into calibration set and validation set. The calibration set was used to set up calibration model and then the model was adopted to predict the samples of validation set. The partial least square regression (PLSR) was used to build calibration model. The results show that the correlation coefficient for cooking loss and shear force are 0.81 and 0.78 respectively. It is feasible and effective that measure cooking loss and shear force of vacuum-packed fresh pork loin using visible/near infrared spectroscopy in interactance mode.


Asunto(s)
Culinaria , Carne/análisis , Espectroscopía Infrarroja Corta , Animales , Calibración , Análisis de los Mínimos Cuadrados , Modelos Teóricos , Porcinos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA